Mason Ashley, Fragapane Lauren, Toledo-Nieves Zuleyma, Moreo Natalie, Aungst Angela, Robertson Derrick, Maldonado Janice
From the Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Department of Neurology, University of South Florida, Tampa, FL, USA.
Int J MS Care. 2024 May-Jun;26(3):104-107. doi: 10.7224/1537-2073.2023-013. Epub 2024 May 16.
Migraines are a common comorbidity and source of disability in patients with chronic inflammatory diseases like multiple sclerosis (MS). Recently, therapeutic agents for episodic and chronic migraine known as calcitonin gene-related peptide (CGRP) inhibitors have shown to effectively control migraine attacks and improve quality of life in the general population. This study explored the use of these novel agents in individuals with comorbid MS.
This was a retrospective, population-based cohort study at the University of South Florida's neurology clinic; it evaluated individuals with both MS and migraine.
A total of 27 individuals with MS and chronic or episodic migraine who received treatment with a CGRP monoclonal antibody were identified. Of these, 63% reported a reduction in their migraine frequency of greater than 75%. Concurrent use of a disease-modifying therapy (DMT) for MS occurred in 82% of patients, and in 37% of these, the DMT used was also a monoclonal antibody. Adverse effects from CGRP monoclonal antibodies were mild and occurred in only 11% of patients, and no patient experienced worsening of their MS symptoms during cotreatment over the duration of the study.
Our study showed a significant reduction in migraine frequency and a favorable adverse event profile for individuals with comorbid MS who took CGRP monoclonal antibodies and experienced no worsening of MS symptoms. In individuals with MS, CGRP monoclonal antibodies seem to be a safe and effective therapy for episodic or chronic migraine.
偏头痛是慢性炎症性疾病（如多发性硬化症，MS）患者常见的合并症和致残原因。最近，一种名为降钙素基因相关肽（CGRP）抑制剂的发作性和慢性偏头痛治疗药物已显示出能有效控制偏头痛发作并改善普通人群的生活质量。本研究探讨了这些新型药物在合并MS的个体中的应用。
这是一项在南佛罗里达大学神经科诊所进行的基于人群的回顾性队列研究；它评估了患有MS和偏头痛的个体。
共确定了27名患有MS和慢性或发作性偏头痛且接受CGRP单克隆抗体治疗的个体。其中，63%的人报告偏头痛频率降低超过75%。82%的患者同时使用了MS疾病修正治疗（DMT），其中37%使用的DMT也是单克隆抗体。CGRP单克隆抗体的不良反应轻微，仅11%的患者出现，并且在研究期间的联合治疗过程中，没有患者的MS症状恶化。
我们的研究表明，对于合并MS且服用CGRP单克隆抗体且MS症状未恶化的个体，偏头痛频率显著降低，不良事件情况良好。在患有MS的个体中，CGRP单克隆抗体似乎是发作性或慢性偏头痛的一种安全有效的治疗方法。
